Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO

The video discusses market concerns and outlines 2018 as a transition year with investments in future growth. It explains the reasons for profit decline, mainly due to currency effects and investments in healthcare. The liquid crystals market is expected to decline but stabilize by 2020. M&A activities are limited due to a focus on deleveraging. The life sciences unit shows strong growth driven by research, process solutions, and applied segments.

What is the company's stance on mergers and acquisitions in the near future?

What are the anticipated effects of the upcoming sale of the consumer health business?

What are the key drivers of growth in the life sciences unit as mentioned in the text?